Bristol Myers Squibb (BMY) Q3 2025 10-Q Quarterly Report
Bristol Myers Squibb (BMY) 10-Q quarterly report for Q3 2025, filed with SEC EDGAR on Oct 30, 2025 for the fiscal period ending Sep 30, 2025. This page provides AI-powered analysis including management discussion & analysis (MD&A), risk factor updates, and key quarterly financial data such as revenue and net income extracted from XBRL.
Bristol Myers Squibb Q3 2025 10-Q Analysis
Management Discussion & Analysis
- • Revenue details not explicitly provided in excerpt; focus on expense trends instead
- • Operating expenses $9.11B Q3 2025 vs $10.22B Q3 2024, down 11% YoY; YTD $27.83B vs $44.51B, down 37% YoY
- • Cost of products sold $3.44B Q3 2025, up 16% YoY; driven by alliance profit sharing and product mix
- • SG&A $1.79B Q3 2025, down 10% YoY due to strategic cost savings; R&D $2.53B Q3, up 6% YoY driven by IPRD impairment
- • Acquired IPRD charges spiked to $633M Q3 2025 from $262M prior year; amortization $831M Q3, down 65% YoY due to Revlimid fully amortized
- • Other income/(expense) net $(108)M Q3 2025 vs $234M expense prior year; includes interest expense $480M Q3, slightly down YoY
- • No direct segment revenue information; largest expense driver noted is product sales and alliance sharing
- • Management notes ongoing strategic productivity initiatives cutting SG&A and R&D costs this year
- • No revised guidance or explicit near-term outlook commentary included in this section
Risk Factors
- • No newly added risk factors explicitly stated this quarter, focus on product approvals updates
- • Regulatory risk from accelerated approvals of Opdivo + Yervoy for multiple indications in Japan, EC, and FDA between Feb-Aug 2025
- • Market risk from increased competition in immuno-oncology given multiple new first-line treatment approvals of Opdivo + Yervoy
- • Operational risk related to integration of expanded portfolio from recent approvals including Camzyos and Breyanzi in Japan and EC
- • Financial risk due to potential revenue concentration on Opdivo + Yervoy with multiple approvals enhancing dependency on these products
Bristol Myers Squibb Q3 2025 Quarterly FinancialsXBRL
Revenue
$12.2B
▲ +2.8% YoY▼ -0.4% QoQ
Net Income
$2.2B
▲ +81.8% YoY▲ +68.0% QoQ
Net Margin
18.0%
▲ +783bp YoY▲ +733bp QoQ
Source: XBRL data from Bristol Myers Squibb Q3 2025 10-Q filing on SEC EDGAR. All figures in USD.
Other Bristol Myers Squibb Quarterly Reports
Get deeper insights on Bristol Myers Squibb
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.